JP2003526595A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003526595A5 JP2003526595A5 JP2000507359A JP2000507359A JP2003526595A5 JP 2003526595 A5 JP2003526595 A5 JP 2003526595A5 JP 2000507359 A JP2000507359 A JP 2000507359A JP 2000507359 A JP2000507359 A JP 2000507359A JP 2003526595 A5 JP2003526595 A5 JP 2003526595A5
- Authority
- JP
- Japan
- Prior art keywords
- eczema
- pharmaceutical composition
- composition according
- active ingredient
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 201000004624 dermatitis Diseases 0.000 claims 18
- 208000005679 Eczema Diseases 0.000 claims 17
- 231100001003 eczema Toxicity 0.000 claims 17
- 239000008194 pharmaceutical composition Substances 0.000 claims 13
- 239000004480 active ingredient Substances 0.000 claims 9
- SHGAZHPCJJPHSC-ZVCIMWCZSA-N (2E,4E,6Z,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraenoic acid Chemical compound OC(=O)/C=C(\C)/C=C/C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-ZVCIMWCZSA-N 0.000 claims 6
- 229960001445 alitretinoin Drugs 0.000 claims 6
- 230000003902 lesions Effects 0.000 claims 6
- 239000011780 sodium chloride Substances 0.000 claims 5
- 208000002029 Allergic Contact Dermatitis Diseases 0.000 claims 4
- 206010012442 Dermatitis contact Diseases 0.000 claims 4
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 claims 4
- 210000002374 Sebum Anatomy 0.000 claims 4
- 230000002950 deficient Effects 0.000 claims 4
- 231100000080 dermatitis contact Toxicity 0.000 claims 4
- -1 sachet Substances 0.000 claims 4
- 208000001875 Irritant Dermatitis Diseases 0.000 claims 3
- 210000004243 Sweat Anatomy 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 239000002775 capsule Substances 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 239000006071 cream Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 150000002148 esters Chemical class 0.000 claims 2
- 239000006210 lotion Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000002674 ointment Substances 0.000 claims 2
- 239000006187 pill Substances 0.000 claims 2
- 239000003826 tablet Substances 0.000 claims 2
- 208000010201 Exanthema Diseases 0.000 claims 1
- 229940023488 Pill Drugs 0.000 claims 1
- 206010037844 Rash Diseases 0.000 claims 1
- 208000008742 Seborrheic Dermatitis Diseases 0.000 claims 1
- 229910052783 alkali metal Inorganic materials 0.000 claims 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 claims 1
- 125000005907 alkyl ester group Chemical group 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 230000037396 body weight Effects 0.000 claims 1
- 231100000406 dermatitis Toxicity 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000005884 exanthem Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000000699 topical Effects 0.000 claims 1
Claims (15)
- ９−シスレチノイン酸並びにその製薬上受容され得る塩及び製薬上受容され得る加水分解可能なエステルから選択された少なくとも１つの化合物を活性成分として含有する、刺激性皮膚炎、アレルギー性接触皮膚炎、べんち性湿疹、汗疱のような外因性湿疹又は脂漏性湿疹、皮脂欠乏性湿疹及び円板状湿疹のような内因性湿疹の処置用の医薬組成物。
- 活性成分を製薬上受容され得る担体との組合せにて含む、請求項１記載の医薬組成物。
- 経口又は局所投与用である、請求項１又は２記載の医薬組成物。
- タブレット、カプセル、丸剤、サッシェ、軟膏、クリーム又はローションの形態である、請求項１ないし３のいずれか１項記載の医薬組成物。
- 活性成分５ないし５０mg、好ましくは１０ないし２０mgを含有するタブレット、カプセル、丸剤又はサッシェの形態である、請求項１ないし４のいずれか１項記載の医薬組成物。
- 体重１kg当たり活性成分０．０５mg〜１．５mg、好ましくは０．３mg〜０．９mgの経口日用投薬量用である、請求項１ないし５のいずれか１項記載の医薬組成物。
- ０．０００５ないし０．０５重量パーセント、好ましくは０．００１ないし０．０１重量パーセントの活性成分を含有する軟膏、クリーム又はローションの形態である、請求項１ないし４及び６のいずれか１項記載の医薬組成物。
- 活性成分を、９−シスレチノイン酸並びにそのアルカリ金属塩、アルカリ土類金属塩、ベンジルエステル、低級アルキルエステル及び９−フルオレニルメチルエステルからなる群から選択する、請求項１ないし７のいずれか１項記載の医薬組成物。
- 活性成分が９−シスレチノイン酸又はその製薬上受容され得る塩である、請求項１ないし８のいずれか１項記載の医薬組成物。
- ９−シスレチノイン酸を含有する、活動性湿疹性病変を含む湿疹様状態の処置用の医薬組成物。
- 湿疹様状態が、刺激性皮膚炎、アレルギー性接触皮膚炎、脂漏性湿疹、皮脂欠乏性湿疹又は円板状湿疹の活動性湿疹性病変を含む、請求項１０記載の医薬組成物。
- 湿疹様状態が、緩解期にある先在性湿疹性病変を含む、請求項１１記載の医薬組成物。
- 湿疹様状態が、病変が緩解期にある刺激性皮膚炎、アレルギー性接触皮膚炎、べんち性湿疹又は汗疱、脂漏性皮膚炎、皮脂欠乏性湿疹又は円板状湿疹の先在性病変を含む、請求項１２記載の医薬組成物。
- ９−シスレチノイン酸並びにその製薬上受容され得る塩及び製薬上受容され得る加水分解可能なエステルから選択された化合物の、刺激性皮膚炎、アレルギー性接触皮膚炎、べんち性湿疹、汗疱のような外因性湿疹又は脂漏性湿疹、皮脂欠乏性湿疹及び円板状湿疹のような内因性湿疹の処置用の薬剤の製造のための活性成分としての使用。
- 活動性湿疹性病変を含む湿疹様状態の処置用の薬剤の製造のための活性成分としての９−シスレチノイン酸の使用。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP97114651.9 | 1997-08-23 | ||
| EP97114651A EP0908179A1 (en) | 1997-08-23 | 1997-08-23 | Treatment of cell-mediated immune diseases |
| PCT/EP1998/005236 WO1999009969A1 (en) | 1997-08-23 | 1998-08-18 | Treatment of cell-mediated immune diseases |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2003526595A JP2003526595A (ja) | 2003-09-09 |
| JP3522220B2 JP3522220B2 (ja) | 2004-04-26 |
| JP2003526595A5 true JP2003526595A5 (ja) | 2005-04-07 |
Family
ID=8227266
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000507359A Expired - Lifetime JP3522220B2 (ja) | 1997-08-23 | 1998-08-18 | 細胞媒介性免疫病の処置 |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US6589989B1 (ja) |
| EP (2) | EP0908179A1 (ja) |
| JP (1) | JP3522220B2 (ja) |
| KR (1) | KR100596260B1 (ja) |
| CN (1) | CN1136845C (ja) |
| AT (1) | ATE259224T1 (ja) |
| AU (1) | AU739440B2 (ja) |
| BR (1) | BRPI9811989B8 (ja) |
| CA (1) | CA2301907C (ja) |
| DE (1) | DE69821624T2 (ja) |
| DK (1) | DK1007020T3 (ja) |
| ES (1) | ES2214729T3 (ja) |
| NO (1) | NO327141B1 (ja) |
| NZ (1) | NZ502812A (ja) |
| PT (1) | PT1007020E (ja) |
| RU (1) | RU2238083C2 (ja) |
| TR (1) | TR200000488T2 (ja) |
| WO (1) | WO1999009969A1 (ja) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8541469B2 (en) * | 1997-08-23 | 2013-09-24 | Glaxo Group Limited | Treatment of cell-mediated immune diseases |
| US20020031539A1 (en) * | 2000-08-30 | 2002-03-14 | The Brigham And Women's Hospital, Inc. | Oxidized forms of retinoic acid as ligands for peroxisome proliferator activated receptor gamma |
| DE10255861A1 (de) * | 2002-11-29 | 2004-06-17 | Axxima Pharmaceuticals Ag | Gegen Hepatitis C-Virusinfektionen nützliche Verbindungen und Substanzen |
| FR2834216B1 (fr) * | 2001-12-27 | 2004-04-30 | Pharmascience Lab | Composition cosmetique ou pharmaceutique comprenant au moins une oxazoline pour inhiber la migration des cellules de langerhans, et ses utilisations |
| JP2004020220A (ja) * | 2002-06-12 | 2004-01-22 | Pioneer Electronic Corp | 通信システム及び方法、通信端末装置、通信センタ装置、並びにコンピュータプログラム |
| TW579640B (en) * | 2002-10-23 | 2004-03-11 | Veutron Corp | Light gathering device of scanner |
| EP1527774A1 (en) | 2003-11-03 | 2005-05-04 | Basilea Pharmaceutica AG | New formulation for retinoid-containing soft gelatin capsules |
| AU2004222279B2 (en) | 2003-03-14 | 2010-01-21 | University Of Washington | Retinoid replacements and opsin agonists and methods for the use thereof |
| KR100743278B1 (ko) | 2003-04-11 | 2007-07-26 | 에프. 호프만-라 로슈 아게 | 9-시스 레티노산의 제조 방법 |
| US7122751B1 (en) * | 2004-01-16 | 2006-10-17 | Cobalt Flux | Switch apparatus |
| CN1921843A (zh) * | 2004-01-23 | 2007-02-28 | 独立行政法人科学技术振兴机构 | 含视黄酸的糖尿病治疗药 |
| AU2012216808B2 (en) * | 2004-06-18 | 2015-04-30 | University Of Washington | Retinal derivatives and methods for the use thereof for the treatment of visual disorders |
| AU2015207903B2 (en) * | 2004-06-18 | 2017-08-17 | University Of Washington | Retinal derivatives and methods for the use thereof for the treatment of visual disorders |
| SI2397133T1 (sl) * | 2004-06-18 | 2017-12-29 | University of Washington Intellectual Property and Technology Transfer | Retinalni derivati in metode za njihovo uporabo pri zdravljenju motenj vida |
| JP5042839B2 (ja) | 2005-09-09 | 2012-10-03 | 有限会社ケムフィズ | 腸疾患の予防及び／又は治療のための医薬 |
| US8324270B2 (en) | 2008-02-11 | 2012-12-04 | University Of Washington | Methods for the treatment and prevention of age-related retinal dysfunction |
| US8580278B2 (en) * | 2009-06-03 | 2013-11-12 | Trustees Of Dartmouth College | Nutraceutical composition and methods for preventing or treating multiple sclerosis |
| JP5663025B2 (ja) | 2009-09-15 | 2015-02-04 | キューエルティー インコーポレイテッド | ９−ｃｉｓ−レチニルエステルを脂質ビヒクル中に含む医薬製剤 |
| US8771693B2 (en) | 2009-10-27 | 2014-07-08 | Beth Israel Deaconess Medical Center, Inc. | Methods and compositions for the generation and use of conformation-specific antibodies |
| WO2011132084A2 (en) | 2010-04-19 | 2011-10-27 | Qlt Inc. | Therapeutic regimen and method for treating or ameliorating visual disorders associated with an endogenous retinoid deficiency |
| WO2012125724A1 (en) | 2011-03-14 | 2012-09-20 | Beth Israel Deaconess Medical Center | Methods and compositions for the treatment of proliferative disorders |
| WO2012149334A2 (en) | 2011-04-27 | 2012-11-01 | Beth Israel Deaconess Medical Center, Inc. | Methods and compositions for the generation and use of conformation-specific antibodies |
| CN102247348A (zh) * | 2011-05-23 | 2011-11-23 | 天津拓飞生物科技有限公司 | 9-顺式维甲酸在制备治疗糖尿病皮肤溃疡的药物中的应用 |
| US9439884B2 (en) | 2011-05-26 | 2016-09-13 | Beth Israel Deaconess Medical Center, Inc. | Methods for the treatment of immune disorders |
| WO2013009945A1 (en) | 2011-07-12 | 2013-01-17 | The Brigham And Women's Hospital, Inc. | Lipid-containing psa compositions, methods of isolation and methods of use thereof |
| CA2865935C (en) | 2012-03-01 | 2021-12-14 | Qlt Inc. | Therapeutic regimens and methods for improving visual function in visual disorders associated with an endogenous retinoid deficiency |
| US9730941B2 (en) | 2012-06-07 | 2017-08-15 | Beth Israel Deaconess Medical Center, Inc. | Methods and compositions for the inhibition of Pin1 |
| US9221854B2 (en) | 2012-08-17 | 2015-12-29 | Basf Se | Isomerization of olefinic compounds |
| JP6461792B2 (ja) | 2012-08-17 | 2019-01-30 | ビーエーエスエフ ソシエタス・ヨーロピアＢａｓｆ Ｓｅ | オレフィン化合物の異性化 |
| US20150202172A1 (en) * | 2014-01-22 | 2015-07-23 | Glaxo Group Limited | Novel method of use |
| US10351914B2 (en) | 2014-07-17 | 2019-07-16 | Beth Israel Deaconess Medical Center, Inc. | Biomarkers for Pin1-associated disorders |
| WO2016011268A1 (en) | 2014-07-17 | 2016-01-21 | Beth Israel Deaconess Medical Center, Inc. | Atra for modulating pin1 activity and stability |
| US10548864B2 (en) | 2015-03-12 | 2020-02-04 | Beth Israel Deaconess Medical Center, Inc. | Enhanced ATRA-related compounds for the treatment of proliferative diseases, autoimmune diseases, and addiction conditions |
| CA2997211A1 (en) | 2015-08-19 | 2017-02-23 | President And Fellows Of Harvard College | Lipidated psa compositions and methods |
| WO2018014012A1 (en) | 2016-07-15 | 2018-01-18 | President And Fellows Of Harvard College | Glycolipid compositions and methods of use |
| CN113499335B (zh) * | 2021-07-13 | 2023-06-20 | 中国人民解放军军事科学院军事医学研究院 | 一种靶向自噬融合治疗神经退行性疾病的药物 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5525635A (en) * | 1986-02-04 | 1996-06-11 | Moberg; Sven | Pharmaceutical compositions containing propylene glycol and/or polyethylene glycol and urea as active main components and use thereof |
| US5093360A (en) * | 1989-04-07 | 1992-03-03 | Yu Ruey J | Retinal, derivatives and their therapeutic use |
| US5057501A (en) * | 1990-03-13 | 1991-10-15 | Dermatologic Research Corporation | Methods for treatment of papulosquamous and eczematous diseases |
| US5932622A (en) * | 1991-12-18 | 1999-08-03 | The Salk Institute For Biological Studies | Method for in vivo modulation of non-malignant skin-related processes with 9-cis-retinoic acid |
| KR100274101B1 (ko) | 1992-01-22 | 2000-12-15 | 프리돌린 클라우스너, 롤란드 비. 보레르 | 9-시스 레틴산을 함유하는 약제학적 조성물 |
| US5750570A (en) * | 1992-03-31 | 1998-05-12 | The Regents Of The University Of Michigan | Method of treatment of hyperpigmentation in black skin with retinoic acid and method of lightening black skin with retinoic acid |
| CA2093577C (en) | 1992-05-07 | 2006-01-03 | Michael Klaus | Alkyl or alkoxy substituted s-heterocyclic retinoids |
| TW272187B (ja) * | 1992-05-20 | 1996-03-11 | Hoffmann La Roche | |
| WO1994022818A1 (en) * | 1993-04-05 | 1994-10-13 | Pfizer Inc. | Method for the preparation of 9-cis retinoic acid |
| US5457129A (en) * | 1993-05-17 | 1995-10-10 | Research Development Foundation | Inhibition of nitric oxide production by retinoic acid |
| FR2717686B1 (fr) * | 1994-03-22 | 1996-06-28 | Fabre Pierre Cosmetique | Composition dermo-cosmétologique et procédé de préparation. |
| DE4415204A1 (de) * | 1994-04-30 | 1995-11-02 | Carl Heinrich Dr Weischer | Neue Retinol (Vitamin A) -Derivate, deren Herstellung und Verwendung als Arzneimittel und Kosmetika |
| FR2728790B1 (fr) * | 1994-12-29 | 1997-01-24 | Cird Galderma | Composition modulant l'apoptose comprenant du methonial ou tout facteur influencant le taux intracellulaire de methonial |
| US6083977A (en) * | 1994-12-30 | 2000-07-04 | Ligand Pharmaceuticals Incorporated | Trienoic retinoid compounds and methods |
| US5837728A (en) * | 1995-01-27 | 1998-11-17 | Molecular Design International | 9-cis retinoic acid esters and amides and uses thereof |
| FR2735367B1 (fr) * | 1995-06-19 | 1997-07-18 | Cird Galderma | Utilisation de ligands specifiques des recepteurs rxrs |
| FR2752734B1 (fr) * | 1996-09-02 | 1998-11-06 | Cird Galderma | Utilisation de retinoides pour la preparation d'un medicament destine a traiter les affections liees a une surexpression de vegf |
| US5994081A (en) * | 1998-04-27 | 1999-11-30 | Incyte Pharamaceuticals, Inc. | Human keratins |
| US20030105031A1 (en) * | 2001-11-06 | 2003-06-05 | Rosenbloom Richard A. | Methods for the treatment of skin disorders |
-
1997
- 1997-08-23 EP EP97114651A patent/EP0908179A1/en not_active Withdrawn
-
1998
- 1998-08-18 TR TR2000/00488T patent/TR200000488T2/xx unknown
- 1998-08-18 WO PCT/EP1998/005236 patent/WO1999009969A1/en not_active Application Discontinuation
- 1998-08-18 US US09/485,943 patent/US6589989B1/en not_active Expired - Lifetime
- 1998-08-18 CA CA002301907A patent/CA2301907C/en not_active Expired - Lifetime
- 1998-08-18 KR KR1020007001813A patent/KR100596260B1/ko active IP Right Grant
- 1998-08-18 CN CNB98808743XA patent/CN1136845C/zh not_active Expired - Lifetime
- 1998-08-18 RU RU2000107124/14A patent/RU2238083C2/ru active
- 1998-08-18 JP JP2000507359A patent/JP3522220B2/ja not_active Expired - Lifetime
- 1998-08-18 DE DE69821624T patent/DE69821624T2/de not_active Expired - Lifetime
- 1998-08-18 ES ES98947437T patent/ES2214729T3/es not_active Expired - Lifetime
- 1998-08-18 DK DK98947437T patent/DK1007020T3/da active
- 1998-08-18 PT PT98947437T patent/PT1007020E/pt unknown
- 1998-08-18 BR BRPI9811989A patent/BRPI9811989B8/pt not_active IP Right Cessation
- 1998-08-18 NZ NZ502812A patent/NZ502812A/en not_active IP Right Cessation
- 1998-08-18 AT AT98947437T patent/ATE259224T1/de active
- 1998-08-18 AU AU94356/98A patent/AU739440B2/en not_active Expired
- 1998-08-18 EP EP98947437A patent/EP1007020B1/en not_active Expired - Lifetime
-
2000
- 2000-02-22 NO NO20000870A patent/NO327141B1/no not_active IP Right Cessation
-
2003
- 2003-06-11 US US10/459,273 patent/US20040039056A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003526595A5 (ja) | ||
| US5292772A (en) | Method for the prevention and control of epileptic seizure associated with Lennox-Gastaut syndrome | |
| ES2244103T3 (es) | Remedio para enfermedades neurodegenerativas. | |
| RU2000107124A (ru) | Лечение опосредуемых клеткой иммунных болезней | |
| CA1198057A (en) | Method of contraception using peak progestogen dosage | |
| US4978680A (en) | Method for the prevention and control of epileptic seizure | |
| JP3305315B2 (ja) | 動物及び人間の疼痛及び／又は炎症の抑制時における薬剤ならびにその製造及びその使用 | |
| JP5441287B2 (ja) | 心血管事象を予防するための必須脂肪酸 | |
| US6025394A (en) | Method for treating patients with acne by administering substituted sulfonyl indenyl acetic acids, amides and alcohols | |
| JP2009102342A5 (ja) | ||
| CA2307879A1 (en) | Treatment of t-helper cell type 2 mediated immune diseases | |
| JP2003508441A5 (ja) | ||
| KR19980064024A (ko) | 약학 조성물 | |
| CA2470703A1 (en) | Oral pharmaceutical products containing 17.beta.-estradiol-3-lower alkanoate, method of administering the same and process of preparation | |
| JPS6352015B2 (ja) | ||
| JP3192141B2 (ja) | 抗うつ剤 | |
| US20080021083A1 (en) | 4-Methylpyrazole Formulations for Inhibiting Ethanol Intolerance | |
| EP0228253A1 (en) | Rectally absorbable form of L-dopa | |
| WO2009069139A1 (en) | Dosage form providing an ibuprofen-containing liquid fill | |
| JPH03206064A (ja) | 速効性かつ鎮痛効果が増強された鎮痛剤としてのｓ（＋）―イブプロフエン―ｌ―アミノ酸とｓ（＋）―イブプロフエン―ｄ―アミノ酸 | |
| AU740875B2 (en) | Novel use of compounds for anti-pruritic activity | |
| US5702723A (en) | Multi-stage delivery system for ingestible medications or nutrients | |
| JPS605580B2 (ja) | 新ナフタレン誘導体の製法 | |
| JP3122748B2 (ja) | イブプロフェン含有解熱鎮痛剤 | |
| JP2834512B2 (ja) | リポキシン誘導体を有効成分とする疾患治療剤 |